vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $185.2M, roughly 1.7× AMICUS THERAPEUTICS, INC.). ALBANY INTERNATIONAL CORP runs the higher net margin — 4.3% vs 0.9%, a 3.4% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 12.0%). ALBANY INTERNATIONAL CORP produced more free cash flow last quarter ($51.4M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
AIN vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $185.2M |
| Net Profit | $13.9M | $1.7M |
| Gross Margin | 31.1% | 85.7% |
| Operating Margin | 9.3% | 8.6% |
| Net Margin | 4.3% | 0.9% |
| Revenue YoY | 12.0% | 23.7% |
| Net Profit YoY | -21.5% | -88.5% |
| EPS (diluted) | $0.56 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $185.2M | ||
| Q3 25 | $261.4M | $169.1M | ||
| Q2 25 | $311.4M | $154.7M | ||
| Q1 25 | $288.8M | $125.2M | ||
| Q4 24 | $286.9M | $149.7M | ||
| Q3 24 | $298.4M | $141.5M | ||
| Q2 24 | $332.0M | $126.7M | ||
| Q1 24 | $313.3M | $110.4M |
| Q4 25 | $13.9M | $1.7M | ||
| Q3 25 | $-97.8M | $17.3M | ||
| Q2 25 | $9.2M | $-24.4M | ||
| Q1 25 | $17.4M | $-21.7M | ||
| Q4 24 | $17.7M | $14.7M | ||
| Q3 24 | $18.0M | $-6.7M | ||
| Q2 24 | $24.6M | $-15.7M | ||
| Q1 24 | $27.3M | $-48.4M |
| Q4 25 | 31.1% | 85.7% | ||
| Q3 25 | -19.1% | 88.5% | ||
| Q2 25 | 31.3% | 90.2% | ||
| Q1 25 | 33.4% | 90.7% | ||
| Q4 24 | 31.5% | 90.1% | ||
| Q3 24 | 30.3% | 90.6% | ||
| Q2 24 | 33.9% | 91.1% | ||
| Q1 24 | 34.7% | 87.7% |
| Q4 25 | 9.3% | 8.6% | ||
| Q3 25 | -44.6% | 20.3% | ||
| Q2 25 | 7.2% | -6.1% | ||
| Q1 25 | 9.8% | -6.3% | ||
| Q4 24 | 8.5% | 10.7% | ||
| Q3 24 | 8.4% | 15.3% | ||
| Q2 24 | 12.9% | 11.8% | ||
| Q1 24 | 12.4% | -25.1% |
| Q4 25 | 4.3% | 0.9% | ||
| Q3 25 | -37.4% | 10.2% | ||
| Q2 25 | 2.9% | -15.8% | ||
| Q1 25 | 6.0% | -17.3% | ||
| Q4 24 | 6.2% | 9.8% | ||
| Q3 24 | 6.0% | -4.8% | ||
| Q2 24 | 7.4% | -12.4% | ||
| Q1 24 | 8.7% | -43.9% |
| Q4 25 | $0.56 | $0.00 | ||
| Q3 25 | $-3.37 | $0.06 | ||
| Q2 25 | $0.31 | $-0.08 | ||
| Q1 25 | $0.56 | $-0.07 | ||
| Q4 24 | $0.57 | $0.05 | ||
| Q3 24 | $0.57 | $-0.02 | ||
| Q2 24 | $0.79 | $-0.05 | ||
| Q1 24 | $0.87 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $293.5M |
| Total DebtLower is stronger | $455.7M | $392.7M |
| Stockholders' EquityBook value | $726.2M | $274.2M |
| Total Assets | $1.7B | $949.9M |
| Debt / EquityLower = less leverage | 0.63× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $293.5M | ||
| Q3 25 | $108.3M | $263.8M | ||
| Q2 25 | $106.7M | $231.0M | ||
| Q1 25 | $119.4M | $250.6M | ||
| Q4 24 | $115.3M | $249.9M | ||
| Q3 24 | $127.2M | $249.8M | ||
| Q2 24 | $116.4M | $260.1M | ||
| Q1 24 | $125.4M | $239.6M |
| Q4 25 | $455.7M | $392.7M | ||
| Q3 25 | $480.6M | $392.0M | ||
| Q2 25 | $444.7M | $391.3M | ||
| Q1 25 | $416.4M | $390.7M | ||
| Q4 24 | $318.5M | $390.1M | ||
| Q3 24 | $362.2M | $389.5M | ||
| Q2 24 | $377.1M | $388.9M | ||
| Q1 24 | $439.1M | $388.4M |
| Q4 25 | $726.2M | $274.2M | ||
| Q3 25 | $739.3M | $230.4M | ||
| Q2 25 | $888.6M | $204.3M | ||
| Q1 25 | $900.0M | $193.6M | ||
| Q4 24 | $943.5M | $194.0M | ||
| Q3 24 | $991.0M | $178.8M | ||
| Q2 24 | $967.5M | $132.5M | ||
| Q1 24 | $967.5M | $130.7M |
| Q4 25 | $1.7B | $949.9M | ||
| Q3 25 | $1.7B | $868.8M | ||
| Q2 25 | $1.7B | $815.3M | ||
| Q1 25 | $1.7B | $789.8M | ||
| Q4 24 | $1.6B | $785.0M | ||
| Q3 24 | $1.8B | $786.6M | ||
| Q2 24 | $1.8B | $749.5M | ||
| Q1 24 | $1.8B | $721.8M |
| Q4 25 | 0.63× | 1.43× | ||
| Q3 25 | 0.65× | 1.70× | ||
| Q2 25 | 0.50× | 1.92× | ||
| Q1 25 | 0.46× | 2.02× | ||
| Q4 24 | 0.34× | 2.01× | ||
| Q3 24 | 0.37× | 2.18× | ||
| Q2 24 | 0.39× | 2.93× | ||
| Q1 24 | 0.45× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $16.3M |
| Free Cash FlowOCF − Capex | $51.4M | $16.0M |
| FCF MarginFCF / Revenue | 16.0% | 8.6% |
| Capex IntensityCapex / Revenue | 6.9% | 0.2% |
| Cash ConversionOCF / Net Profit | 5.31× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $16.3M | ||
| Q3 25 | $43.9M | $35.7M | ||
| Q2 25 | $32.7M | $-26.5M | ||
| Q1 25 | $2.1M | $7.8M | ||
| Q4 24 | $78.5M | $-3.9M | ||
| Q3 24 | $47.0M | $-23.0M | ||
| Q2 24 | $83.4M | $22.7M | ||
| Q1 24 | $9.6M | $-29.7M |
| Q4 25 | $51.4M | $16.0M | ||
| Q3 25 | $25.9M | $35.3M | ||
| Q2 25 | $18.8M | $-28.9M | ||
| Q1 25 | $-13.5M | $7.5M | ||
| Q4 24 | $60.2M | $-4.2M | ||
| Q3 24 | $31.6M | $-23.3M | ||
| Q2 24 | $63.6M | $21.6M | ||
| Q1 24 | $-17.3M | $-31.5M |
| Q4 25 | 16.0% | 8.6% | ||
| Q3 25 | 9.9% | 20.9% | ||
| Q2 25 | 6.0% | -18.7% | ||
| Q1 25 | -4.7% | 6.0% | ||
| Q4 24 | 21.0% | -2.8% | ||
| Q3 24 | 10.6% | -16.5% | ||
| Q2 24 | 19.2% | 17.0% | ||
| Q1 24 | -5.5% | -28.5% |
| Q4 25 | 6.9% | 0.2% | ||
| Q3 25 | 6.9% | 0.2% | ||
| Q2 25 | 4.5% | 1.6% | ||
| Q1 25 | 5.4% | 0.2% | ||
| Q4 24 | 6.4% | 0.2% | ||
| Q3 24 | 5.2% | 0.3% | ||
| Q2 24 | 6.0% | 0.9% | ||
| Q1 24 | 8.6% | 1.6% |
| Q4 25 | 5.31× | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 4.44× | -0.27× | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
